AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Close-up view of a vivid blue railway signal light illuminating a track at golden hour sunset, providing crucial safety guidance for efficient train operations and future transportation

CAR-T

Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle

Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this space. Eli Lilly, AbbVie, AstraZeneca and more are up for the challenge.

July 27, 2026

8 min read

Tristan Manalac

Psychedelics

Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates

Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals.

July 24, 2026

3 min read

Gabrielle Masson

Image of Harvard University and pedestrian bridge on Charles River in Cambridge, Massachusetts

Job Trends

6 companies hiring in Cambridge now

Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.

July 22, 2026

1 min read

Angela Gabriel

Podcast

Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.

July 22, 2026

1 min read

Jef Akst

Psychology, Dream, Mental Health concept illustration. Brain, neuroscience and creative mind poster, cover. Vector modern illustration

Psychedelics

Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics

Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst cautioned, however, that the transaction should not be seen as “supporting a uniform re-rating of every psychedelic developer.”

July 20, 2026

3 min read

Heather McKenzie

Paper plane go to success goal vector business financial concept start up, leadership, creative idea symbol paper art style

Earnings

Q2 earnings arrive as pharma picks up steam, buoyed by dealmaking, policy tailwinds

Biopharma is entering its second-quarter earnings season riding high on a wave of massive deals and venture capital flow, plus a clearing of regulatory and policy overhangs. What can industry watchers expect to hear on the upcoming investor calls?

July 15, 2026

6 min read

Tristan Manalac

Podcast

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.

July 8, 2026

1 min read

Jef Akst